Anti-CD20 (Ofatumumab biosimilar - IgG1 isotype)

Human IgG1 monoclonal antibody (mAb) against human CD20

Anti-hCD20-Of-hIgG1 features a human IgG1 constant region (Fc) and the variable region of Ofatumumab which targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.

Ofatumumab is a fully human type I (first generation) monoclonal antibody that mediates B cell destruction through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Ofatumumab has been approved by the FDA for the treatment of chronic lymphocytic leukaemia (CLL)  [1-3].

InvivoGen’s Anti-hCD20-Of-hIgG1 is generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below).
InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Obinutuzumab, with either native or engineered Fc region.

 Read our review on Antibody Isotypes

References:

1. Baig NA. et al., 2014. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol. 192(4):1620-9.
2. Lin TS., 2010. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 3:51-9.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.

Figures

Binding of Anti-hCD20-Of-hIgG1 mAb to hCD20. EL4-hCD20 cells were incubated for 30 minutes at 4°C with 500 ng of Anti-hCD20-Of-hIgG1 or an isotype control. Subsequently, a secondary PE-labeled antibody was added and incubated at 4°C for 30 minutes. The binding affinity was assessed using flow cytometry

Specifications

Target: Human CD20
Clonality: Monoclonal antibody
Isotype: Human IgG1, kappa
Source: CHO cells
Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose and stabilizing agents
Purity: Purified by affinity chromatography with protein G

Tested application: Flow cytometry

Quality control:

• Binding of Anti-hCD20-Of-hIgG1 to human CD20 has been tested using flow cytometry.
• The complete sequence of this antibody has been verified.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

Contents

• 100 µg purified Anti-hCD20-Of-hIgG1 monoclonal antibody (mAb), provided azide-free and lyophilized

Anti-hCD20-Of-hIgG1 is shipped at room temperature.

Store lyophilized antibody at -20 °C.